Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

Kalincik, Tomas; Havrdova, Eva; Horakova, Dana; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Grammond, Pierre; Onofrj, Marco; Lugaresi, Alessandra; ÖZAKBAŞ, SERKAN; Kappos, Ludwig; Kuhle, Jens; TERZİ, MURAT; Lechner-Scott, Jeannette; BOZ, CAVİT; Grand'Maison, Francois; Prevost, Julie; Sola, Patrizia; Ferraro, Diana; Granella, Franco; Trojano, Maria; Bergamaschi, Roberto; Pucci, Eugenio; Turkoglu, Recai; McCombe, Pamela; Van Pesch, Vincent; Van Wijmeersch, Bart; Solaro, Claudio; Ramo-Tello, Cristina; Slee, Mark; Alroughani, Raed; Yamout, Bassem; Shaygannejad, Vahid; Spitaleri, Daniele; Luis Sanchez-Menoyo, Jose; Ampapa, Radek; Hodgkinson, Suzanne; KARABUDAK, RANA; Butler, Ernest; Vucic, Steve; Jokubaitis, Vilija; Spelman, Tim; Butzkueven, Helmut

doi:10.1136/jnnp-2018-319831

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

Atıf İçin Kopyala

Kalincik T., Havrdova E. K. , Horakova D., Izquierdo G., Prat A., Girard M., ...Daha Fazla

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, cilt.90, ss.458-468, 2019 (SCI İndekslerine Giren Dergi)

Cilt numarası: 90 Konu: 4
Basım Tarihi: 2019
Doi Numarası: 10.1136/jnnp-2018-319831
Dergi Adı: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Sayfa Sayıları: ss.458-468

Özet

Objective Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.